Author: Lin Lifeng

  From next year in Hangzhou, insured persons who receive "test-tube baby" treatment in specific hospitals will be reimbursed up to 3,000 yuan.

Policy implementation

Expenses for "test-tube babies" will be reimbursed next year in Hangzhou

  According to Zhejiang Daily, starting next year, residents who participate in Hangzhou's commercial supplementary medical insurance "West Lake Yilianbao" will receive a reimbursement of up to 3,000 yuan for insured citizens who implement assisted reproduction in 2023.

Assisted reproductive technology is included in the medical insurance reimbursement policy.

  In terms of specific reimbursement, "West Lake Yilianbao" will provide a certain amount of subsidies for the expenses of embryo culture and embryo transfer in the provincial and municipal top three medical institutions with specific assisted reproduction qualifications in Hangzhou during the treatment period. The reimbursement limit for cultivation expenses is 1,500 yuan/year, and the reimbursement limit for embryo transfer expenses is 1,500 yuan/year.

  According to reports, embryo culture and embryo transfer are two important items in assisted reproduction. In Hangzhou Obstetrics and Gynecology Hospital, Zhejiang Province Obstetrics and Gynecology Hospital, Run Run Shaw Hospital and other qualified tertiary hospitals, embryo culture charges are charged at each time The fee ranges from 2,000 yuan to 6,000 yuan, and the embryo transfer fee is around 2,000 yuan each time.

After the implementation of targeted subsidies, most of the two treatment expenses of the insured will be borne by "West Lake Yilianbao".

  "West Lake Yilianbao" is the first inclusive medical insurance under the guidance and support of Hangzhou Municipal Medical Insurance Bureau, jointly underwritten by China Life Insurance, PICC Property Insurance, Taikang Life Insurance, and Ping An Property Insurance.

As of November 22, the number of participants in the 2023 "West Lake Yilianbao" that has been online for 21 days has exceeded 3 million.

Policy supports the inclusion of assisted reproduction in medical insurance

There are already intentions in many places

  On August 17 this year, 17 departments including the National Health and Medical Commission and the National Development and Reform Commission issued the "Guiding Opinions on Further Improving and Implementing Active Fertility Support Measures", which clearly stated for the first time that local governments should gradually implement appropriate childbirth analgesia and assisted reproductive technology projects. Included in the medical insurance (including maternity insurance) fund payment scope according to the procedure.

  Previously, many places had intended to include assisted reproduction in medical insurance.

In February of this year, the Beijing Medical Insurance Bureau issued a notice to include 16 items of assisted reproductive technology such as intrauterine artificial insemination and embryo transfer, which are common in outpatient treatment, into the medical insurance.

However, the implementation of this policy was later suspended. As of the latest, the inclusion of assisted reproduction in Beijing has not yet been implemented.

  The Hunan Provincial Medical Insurance Bureau replied in May this year that it will gradually explore the scope of medical insurance payment for therapeutic assisted reproductive technology that can be covered by medical insurance.

The Suzhou Municipal Medical Insurance Bureau also stated this year that assisted reproductive technology, which has a large clinical demand, will be included in the scope of medical insurance payment in a timely manner.

The Zhejiang Provincial Health Commission also stated this year that it will actively promote the inclusion of assisted reproductive technology in medical insurance.

  In addition to the above-mentioned places, more than a dozen provinces including Fujian, Jiangsu, Guangdong, Jiangxi, and Sichuan have introduced three-child implementation policies, all of which mention assisted reproduction.

At the same time, Jiangxi, Sichuan, Hubei and other places have also announced plans to include assisted reproductive technology projects in medical insurance.

  In addition, many places have also issued relevant policies to promote fertility in due course.

Twelve provinces and cities including Shanghai, Hebei, Henan, and Tianjin have released the "Plan for the Application of Human Assisted Reproductive Technology (2021-2025)", and all provinces and cities have expressed in the "Plan" that they will increase the number of human assisted reproductive service institutions.

my country's assisted reproductive market has broad prospects

  As an emerging market for assisted reproduction in my country, there may be a blue ocean market of tens of billions behind it.

  According to data released by the National Health and Medical Commission and the China Population Association, the infertility rate of couples of childbearing age in China has climbed from 2.5%-3% 20 years ago to about 12%-15% in recent years. 50 million people.

  In 2022, the penetration rate of assisted reproductive services in the United States will reach 32.5%, while the penetration rate of assisted reproductive services in China is only 8.7%, which is 23.8% lower than that in the United States. This also means that the scale of China's assisted reproductive service industry will continue to expand in the next 30 years.

  In 2020, the scale of China's assisted reproductive industry has reached 43.41 billion yuan.

With the rising infertility rate in China, the increase in the number of infertile couples and the increasing willingness to accept IVF and other factors, the overall market size of the assisted reproductive industry will continue to grow rapidly.

According to the Toubao data report, the market size of China's assisted reproductive industry will reach 85.43 billion yuan by 2025.

  Kaiyuan Securities Research Institute estimates that the annual compound rate of the assisted reproductive market from 2018 to 2023 is 9.64%. By 2023, the test-tube baby market is expected to increase to 40 billion yuan, and it is expected to exceed 100 billion yuan in the long run.

A number of listed companies have entered the assisted reproductive track

  According to the statistics of Securities Times·Databao, among the A-shares, many listed companies have entered the assisted reproductive track.

Last year, Meditech signed a strategic partnership with Jinxin Fertility to jointly build the flagship reproductive center "Jinxin-Maddy". In addition, the company also acquired Haikou Mary Hospital Co., Ltd. to lay out the field of assisted reproduction.

  International Medicine announced in October this year that its affiliated hospital, Xi'an High-tech Hospital, was approved to trial run conventional in vitro fertilization-embryo transfer and intracytoplasmic sperm microinjection for a period of one year.

  Jiachen Hospital, a wholly-owned subsidiary of Dajia Weikang, has built an assisted reproduction (IVF) center, including embryo culture rooms, semen processing rooms, transplantation operating rooms, and embryo freezing rooms.

  Hanshang Group will deploy Wuhan Tongji Reproductive Hospital in 2021.

Tongji Reproductive Hospital is a leading assisted reproductive institution in China. It not only has the only human sperm bank in Hubei Province, but also the first approved fertility preservation center in Hubei Province.

  In addition to the above-mentioned hospitals that directly own assisted reproductive technology, there are also Sinopharm Modern, Shengnuo Biologics, Shuanglu Pharmaceutical, Xianju Pharmaceutical, and Gonggong Pharmaceutical, etc., which are in the field of drugs and equipment required for assisted reproduction.

  Since the beginning of this year, concept stocks related to assisted reproduction have performed generally.

Leaders such as Hanshang Group and Dajia Weikang fell by more than 20%, and Changhong Technology, Gonggong Pharmaceutical, and Shengnuo Biotech fell by more than 30%. Only one stock in Madi Technology bucked the market and rose by more than 20% during the year.

  In terms of performance, Watson Bio, Changhong Technology, and Madi Technology increased their net profits by more than 20% in the first three quarters of this year, while Xianju Pharmaceutical, Heavy Pharmaceutical Holdings, and Hanshang Group increased their net profits by more than 10%.